Sort By

Phospho-JAK2 (Tyr1007, Tyr1008) Antibody (18HCLC), ABfinity™ Rabbit Oligoclonal (Invitrogen™)

Phospho-JAK2 (Tyr1007, Tyr1008) Oligoclonal Antibody for Western Blot, IF, ICC

JAK2 Recombinant Human Protein, JH1 and JH2 Domains

JAK2 is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways and is mutated in polycythemia vera. This kinase contains both the JH1 (catalytic) and JH2 (pseudokinase) domains of JAK2.

Phospho-JAK2 (Tyr1007, Tyr1008) Antibody (18H13L8), ABfinity™ Rabbit Monoclonal (Invitrogen™)

Phospho-JAK2 (Tyr1007, Tyr1008) Monoclonal Antibody for Western Blot

LanthaScreen™ STAT5 (JAK2 V617F) U2OS Cell Line

LanthaScreen® GFP Cellular Assays allow for the analysis of post-translational modifications for a number of target proteins in an live-cell context. The JAK2⁄STAT5 signaling pathway plays an essential role in blood cell formation in response to cytokines such as GM-CSF, IL-3, and EPO. The recent discovery of an activating mutation in JAK2 (V617F) present in high percentage of myeloproliferative disease (MPD) patients suggests that this mutant JAK2 activity is a potential therapeutic target for certain forms of MPD. The assay described in this summary makes use of a cell line engineered for expression of the constitutively-active mutant kinase JAK2 V617F. By co-expressing GFP-STAT5 in this background, the phosphorylation state of STAT5 (specifically residue Tyr 694⁄699) can be modulated with JAK2 V617F inhibitors and analyzed in cell lysates using an anti-STAT5 [pTyr 694⁄699] and LanthaScreenTM terbium-anti-mouse antibody pair. GFP-STAT5 Lentivirus was transduced into U2OS cells followed by selection with Blasticidin. The selected pool was then transfected with a GST-JAK2 V617F construct using LipofectamineTM LTX, followed by selection with Geneticin. This cell line is a clonal population isolated by flow cytometry using GFP fluorescence as sorting marker, and has been screened for the constitutive expression of GFP-STAT5 and GST-JAK2 V617F. Using a lytic TR-FRET immuno-assay, this cell line is validated for IC50 and Z' under optimized conditions using JAK Inhibitor I (Pyridone 6) as a small molecule inhibitor for JAK2 V617F-mediated GFP-STAT5 phosphorylation. This assay has also been tested for assay performance under variable experimental conditions, including cell plating density, stimulation time, DMSO tolerance and lysis⁄equilibration time.

JAK2 Recombinant Human Protein

Janus kinase 2 (JAK2) is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways and is mutated in polycythemia vera. This kinase contains the catalytic domain (JH1) of JAK2.

JAK2 Monoclonal Antibody (691R5) (Invitrogen™)

JAK2 Monoclonal Antibody for Western Blot

JAK2 [V617F] Recombinant Human Protein, JH1 and JH2 Domains

JAK2 is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. This kinase contains both the JH1 (catalytic) and JH2 (pseudokinase) domains of JAK2. The V617F mutation has been shown to be a cause of polycythemia vera.

JAK2 (Phospho) [pY1007/pY1008] Human ELISA Kit (Invitrogen™)

JAK2 (Phospho) [pY1007/pY1008] Human ELISA Kit for ELISA

JAK2 Polyclonal Antibody (Invitrogen™)

JAK2 Polyclonal Antibody for Western Blot

Phospho-JAK2 (Tyr1007, Tyr1008) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2 (Tyr1007, Tyr1008) Polyclonal Antibody for Western Blot

JAK2 (Total) Human ELISA Kit (Invitrogen™)

JAK2 (Total) Human ELISA Kit for ELISA

JAK2 Antibody (18H11L8), ABfinity™ Rabbit Monoclonal (Invitrogen™)

JAK2 Monoclonal Antibody for Western Blot, IF, ICC

Phospho-JAK2 (Tyr570) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2 (Tyr570) Polyclonal Antibody for Western Blot

JAK2 Monoclonal Antibody (1C1) (Invitrogen™)

JAK2 Monoclonal Antibody for Western Blot

Phospho-JAK2/JAK3 (Tyr966, Tyr939) Polyclonal Antibody (Invitrogen™)

Phospho-JAK2/JAK3 (Tyr966, Tyr939) Polyclonal Antibody for Western Blot